Trade Galectin Therapeutics Inc. - GALT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0400 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.205 |
| Open | 1.2 |
| 1-Year Change | -31.68% |
| Day's Range | 1.175 - 1.2 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 21, 2025 | 1.2050 | 0.0150 | 1.26% | 1.1900 | 1.2150 | 1.0900 |
| Jan 17, 2025 | 1.2150 | -0.0050 | -0.41% | 1.2200 | 1.2650 | 1.1900 |
| Jan 16, 2025 | 1.2350 | -0.0050 | -0.40% | 1.2400 | 1.2650 | 1.2250 |
| Jan 15, 2025 | 1.2550 | 0.1050 | 9.13% | 1.1500 | 1.2650 | 1.1500 |
| Jan 14, 2025 | 1.1250 | 0.0550 | 5.14% | 1.0700 | 1.1450 | 1.0500 |
| Jan 13, 2025 | 1.0850 | 0.0150 | 1.40% | 1.0700 | 1.0950 | 1.0500 |
| Jan 10, 2025 | 1.0750 | -0.0550 | -4.87% | 1.1300 | 1.1450 | 1.0500 |
| Jan 8, 2025 | 1.1250 | -0.0450 | -3.85% | 1.1700 | 1.1750 | 1.1150 |
| Jan 7, 2025 | 1.1850 | -0.0100 | -0.84% | 1.1950 | 1.2450 | 1.1850 |
| Jan 6, 2025 | 1.1750 | -0.0050 | -0.42% | 1.1800 | 1.2650 | 1.1550 |
| Jan 3, 2025 | 1.1550 | 0.0150 | 1.32% | 1.1400 | 1.2000 | 1.1200 |
| Jan 2, 2025 | 1.1750 | -0.1050 | -8.20% | 1.2800 | 1.3650 | 1.1750 |
| Dec 31, 2024 | 1.2850 | 0.1850 | 16.82% | 1.1000 | 1.3050 | 1.1000 |
| Dec 30, 2024 | 1.0850 | 0.1149 | 11.84% | 0.9701 | 1.2250 | 0.9701 |
| Dec 27, 2024 | 1.1150 | 0.2250 | 25.28% | 0.8900 | 1.4300 | 0.8850 |
| Dec 26, 2024 | 0.8551 | 0.0401 | 4.92% | 0.8150 | 0.9222 | 0.8150 |
| Dec 24, 2024 | 0.8100 | -0.0425 | -4.99% | 0.8525 | 0.8525 | 0.7431 |
| Dec 23, 2024 | 0.8700 | -0.0249 | -2.78% | 0.8949 | 0.8981 | 0.8318 |
| Dec 20, 2024 | 1.0050 | -0.1950 | -16.25% | 1.2000 | 1.4700 | 0.7138 |
| Dec 19, 2024 | 1.9850 | -0.0350 | -1.73% | 2.0200 | 2.0600 | 1.8800 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
Galectin Therapeutics Inc. Company profile
About Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.
Financial summary
BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).
Equity composition
Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.
| Industry: | Biotechnology & Medical Research (NEC) |
Suite 240
4960 Peachtree Industrial Boulevard
NORCROSS
GEORGIA 30071
US
News
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024People also watch
Still looking for a broker you can trust?
Join the 680,000+ traders worldwide that chose to trade with Capital.com